Elevated serum IL-10/IL-6 ratio as a novel biomarker for secondary central nervous system lymphoma and poor prognosis in DLBCL
In DLBCL, an elevated serum IL-10/IL-6 ratio at diagnosis independently predicts disease progression and SCNSL risk. Incorporating this biomarker enhances the prognostic utility of both CNS-IPI and NCCN-IPI models. Additionally, the markedly elevated CSF IL-10/IL-6 ratio in SCNSL patients suggests potential diagnostic value for CNS involvement, warranting further investigation.
Authors
- Fang Xu (ORCID: https://orcid.org/0000-0002-6731-1116)
- Xiaogong Liang (ORCID: https://orcid.org/0000-0003-3429-7562)
- Jing Su (ORCID: https://orcid.org/0000-0003-2508-6771)
- Jingjing Wen (ORCID: https://orcid.org/0000-0002-6994-9025)
- Ya Zhang (ORCID: https://orcid.org/0000-0002-0426-333X)
- Xin Nie (ORCID: https://orcid.org/0000-0003-1820-9999)
- Yiping Liu (ORCID: https://orcid.org/0000-0001-8680-9449)
- Jing Yue (ORCID: https://orcid.org/0000-0002-8936-0162)
- Qiaolin Zhou (ORCID: https://orcid.org/0000-0003-0022-0567)
Institutions
- Mianyang Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1656044
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Electronic Science and Technology of China